Fractional Laser-Assisted Hair Regrowth and Microneedling for the Treatment of Alopecia Areata: A Review

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This review discusses the psychological impact of alopecia on women and reports no new clinical findings, highlighting the effect on self-esteem and quality of life.

This case series found that combining ablative fractional resurfacing and acoustic pressure ultrasound with triamcinolone treatment led to complete recovery in patients with areata alopecia.

Microneedling combined with triamcinolone can safely stimulate faster hair regrowth in people with Alopecia Areata.

This study found that non-ablative and/or ablative fractional lasers promoted hair growth in patients with certain uncommon hair disorders, though effectiveness varied among different conditions.

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

This study found that photodynamic therapy with methyl 5-aminolevulinic acid was ineffective for treating alopecia totalis, even with microneedle rolling to enhance drug delivery.

This review discusses the histopathological diagnosis of scarring and non-scarring alopecias, emphasizing the importance of adequate tissue sampling and clinical information; it reports no new empirical results.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This review examines the histopathologic features of four common types of noncicatricial alopecia and reports no new clinical results.

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.

3% topical minoxidil effectively treats extensive alopecia areata.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

This study found no significant difference in hair growth between patients with extensive alopecia areata treated with 1% minoxidil and those given a placebo.

This study found that 1% topical minoxidil induced significant hair regrowth in patients with alopecia areata, though it was less effective for those with extensive hair loss such as alopecia totalis and universalis.